RESPINOR AS

Their core work

Respinor is a Norwegian medical technology SME developing continuous diaphragm monitoring devices for patients on mechanical ventilation in intensive care units. Their core product uses ultrasound-based sensing to track diaphragm activity in real time, helping clinicians decide when a patient is ready to be weaned off a ventilator. The work sits at the intersection of critical-care medicine, medical device engineering, and non-invasive patient monitoring. In short, they build clinical hardware that aims to shorten ICU stays and reduce ventilator-induced complications.

What they specialise in

How they've shifted over time

Respinor's H2020 trajectory is narrow and deliberate: a 2016 SME Phase 1 feasibility study to validate the market and technical concept of continuous diaphragm monitoring, followed directly by a EUR 2.99M SME Phase 2 project (2017-2020) to develop, clinically test and prepare the product for market. Rather than broadening their topic, they deepened a single product line, moving from feasibility assessment to clinical-grade device development. The company is a classic single-product deep-tech SME rather than a multi-domain research group.

They are heading toward clinical deployment and commercialisation of their diaphragm monitoring device, making them relevant for partners interested in ICU validation studies, distribution, or integration with ventilator ecosystems.

How they like to work

Respinor used H2020 as a single-beneficiary SME instrument pathway, coordinating both of their projects without recorded consortium partners. This pattern is typical of a product-focused medical technology SME that treats EU funding as product development capital rather than as a collaboration vehicle. Partners should expect a company that drives its own roadmap and would join a consortium as the clinical-device owner rather than as a generic research contributor.

No recorded consortium partners across their two H2020 projects, reflecting the single-beneficiary SME instrument scheme. Their footprint is Norway-centred with an implicit European market horizon through the SME-2 commercialisation project.

What sets them apart

Respinor is one of very few European SMEs focused specifically on continuous, non-invasive diaphragm monitoring for ventilated ICU patients — a narrow clinical niche with direct implications for weaning protocols and ICU length of stay. They have taken a product through the full SME instrument pipeline, from feasibility to clinical development with nearly EUR 3M of EC funding. Partner with them if you need a dedicated medical device company with a validated product in critical-care respiratory monitoring, not a generalist research group.

Highlights from their portfolio

• DiaMon (SME-2)
  EUR 2.99M single-beneficiary SME Phase 2 grant (2017-2020) to develop and clinically validate the continuous diaphragm monitoring device for ICU use — their flagship project.
• DiaMon (SME-1)
  EUR 50,000 feasibility study in 2016 that directly seeded the successful Phase 2 award, showing a clean SME instrument progression.